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•Evidence-based medicine
- is psychiatry ready?
Evidence-based medicine is a phenomenon that is sweeping
across medicine. There are a number of reasons for this.
Firstly, it is a response to an earlier period when treatments
were anecdotal and poorly supported by empirical data.
Treatments were often based on an extrapolation of
pathophysiological principles and logic. 1 Other treatments
developed on the basis of endorsement by authoritative
proponents. Nowhere was this more apparent than in
psychiatry, where treatment schools evolved on the
charisma of a few leaders (e.g. Jungian psychotherapy,
Freeman and frontal lobotomy). This has increasingly made
way for a research-based approach to medical care, in
which only those interventions validated by methodologically
rigorous study are regarded as acceptable.2 Lastly, external
influences such as managed care are embracing the
evidence-based approach. Having started as a cost-
containment exercise aimed at eliminating unnecessary
investigations and treatments, managed care organisations
are increasingly defining treatment algorithms for many
conditions based on the available evidence of efficacy.
Clearly it would be ideal if treatment guidelines could be
drawn up solely on the basis of data validated by replicated,
large, well-controlled, multicentre trials. There could be no
losers in this scenario; patients would have access to
optimal care, practitioners could sleep at night knowing that
the treatment algorithms they used were based on the best
available knowledge, and third-party reimbursers could be
assured that their finances were appropriately allocated.
Under such circumstances, it would be ethically untenable
to expose patients to treatments the efficacy and tolerability
of which is not adequately established. Similarly, from a
medicolegal perspective, the evidence-based approach is
undeniable solid ground.
How close are we to this ideal state? One of the problems
of this approach is that the standards that define a study as
adequate have become markedly more rigorous with time.
Multicentre international trials with sample sizes of
thousands of patients are now commonplace. The resources
available to do this quality of trial are restricted to the large
multinational pharmaceutical companies for purposes of
new drug development.3 This is a substantial problem for
many older treatments, which were accepted into clinical
practice on the basis of clinical trial data that are suboptimal
by today's standards. Lithium is such a casualty; and the
absence of any financial incentive implies that large,
controlled and long-term studies are unlikely to be done.
Other research 'orphans' include treatments for conditions
which are rare (e.g. autism)., or, because they are endemic in
areas outside the First World, elude First-World interest and
finance (e.g. malaria), or for which little new drug
development is underway (e.g. mania). Indeed, even some
important and common clinical areas are profoundly
deficient in controlled data. Decisions nevertheless have to
be made. An example is the issue of the length of
maintenance antidepressant therapy; very few good data are
available to guide in this area.
Clinical trials currently have extensive exclusion criteria:
medically ill patients, patients on concomitant medical or
psychiatric drugs, substance abusers, patients with comorbid
psychiatric illnesses, and patients with personality disorders
are typically excluded. It is therefore debatable whether
findings of these trials can be applied to the large group of
patients who would not have met the entrance criteria.
So where does this leave evidence-based practice? It
remains the ideal state, where ample data would exist to
validate each treatment choice. Certainly there are areas
where this is the case, such as the utility of neuroleptics in
schizophrenia. In areas where data are clear, deviation from
accepted practice is becoming increasingly difficult to justify.
At the same time, psychiatry is littered with treatments for
which little or no data exist; it is becoming difficult to justify
use of these modalities, particularly if substantiated
alternatives exist. However, decisions frequently need to be
made where there is a relative paucity of methodologically
rigorous data. A common example is where first-line and
well-established therapies have failed.
The validation by methodologically rigorous trials of
treatments that have eluded such scrutiny must become a
priority" In situations where a clear body of quality data
exists, there can be little justification for deviation from
guidelines based on that evidence. However, flexibility is
essential in situations removed from the optimal. Evidence-
based care should be embraced with caution. Psychiatry
remains an immature discipline with a significant art to
science ratio, the body of available knowledge is
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